Novartis’ Haseeb Ahmad is set to become president of the The Association of the British Pharmaceutical Industry (ABPI), where he will take over the role vacated by Erik Nordkamp and lead on overseeing both the ABPI, the ABPI Board and the ABPI’s Code of Practice.
In his new role he will take advantage of the opportunities presented by science, technology and data to help get new medicines to patients faster, whilst promoting innovation and collaboration with the NHS and government, which will not only improve outcomes for patients but also boost the UK economy.
Haseeb said of his appointment: “We are in a golden era of medicines discovery, where innovative science is converging with a data and digital revolution. These forces are coming together to treat and potentially cure diseases on a scale the likes of which we’ve not seen before.”
Haseeb is Novartis UK country president and managing director UK & Ireland of Novartis, and has held senior in-country appointments, including managing director for MSD in Greece during the economic crisis, and above-country roles in Strategy, Operations, Sales and Marketing.
He continued, “The pharmaceutical industry, Government and the NHS must work together to ensure that patients can access innovative therapies and that we deliver the kind of healthcare that all of us in the UK deserve.”
Haseeb has previously led the American Chamber of Commerce Pharma Group, is a member of the ABPI board and Novartis European Executive Committee. He is recognised as a leader who enables winning performance by working collaboratively with customers and has a passion for innovation in healthcare delivery.
By Anna Smith
Source: Pharma Times
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
